Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡

Cited by (1,007)

Items 201–300 of 1,007

1. Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment
   Srikanta Dash, Yücel Aydın, Kyle Widmer, Leela Nayak · 2020 · Journal of Hepatocellular Carcinoma
2. Intra-Hepatic Depletion of Mucosal-Associated Invariant T Cells in Hepatitis C Virus-Induced Liver Inflammation
   Fabian Johannes Bolte, Ashley C. Bolte, Lauren M. Webb, Elisavet Serti, Elenita Rivera, T. Jake Liang, Marc G. Ghany, Barbara Rehermann · 2017 · Gastroenterology
3. Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand?
   Shaheen Tomah, Naim Alkhouri, Osama Hamdy · 2020 · Clinical Diabetes and Endocrinology
4. Clinicopathological characteristics and metabolic profiles of non-alcoholic fatty liver disease in Indian patients with normal body mass index: Do they differ from obese or overweight non-alcoholic fatty liver disease?
   Ramesh K. Kumar, Archana Rastogi, ManojKumar Sharma, Vikram Bhatia, Hitendra Garg, Chhagan Bihari, S.K. Sarin · 2013 · Indian Journal of Endocrinology and Metabolism
5. Noninvasive Assessment of Liver Fibrosis
   Laurent Castéra, Mary E. Rinella, Emmanuel A. Tsochatzis · 2025 · New England Journal of Medicine
6. A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial
   Sunil Suhas Solomon, Sandra Wagner Cardoso, Laura M Smeaton, Leonard Anang Sowah, Chanelle Wimbish, Gregory K. Robbins, Irena Brates, Christine Scello, Annie Son, Anchalee Avihingsanon et al. · 2022 · The Lancet. Gastroenterology & hepatology
7. Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras
   Marina B. Klein, Keri N. Althoff, Yuezhou Jing, Bryan M. Lau, Mari M. Kitahata, Vincent Lo Re, Gregory Dale Kirk, Mark Hull, H. Nina Kim, Giada Sebastiani et al. · 2016 · Clinical Infectious Diseases
8. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications
   Stefano Ciardullo, Emanuele Muraca, Silvia Perra, Eleonora Bianconi, Francesca Zerbini, Alice Oltolini, Rosa Cannistraci, Paola Parmeggiani, Giuseppina Manzoni, Amalia Gastaldelli et al. · 2020 · BMJ Open Diabetes Research & Care
9. Non invasive tools for the diagnosis of liver cirrhosis
   Maurizio Soresi · 2014 · World Journal of Gastroenterology
10. Non‐invasive tests for fibrosis and liver stiffness predict 5‐year survival of patients chronically infected with hepatitis B virus
    Victor de Lédinghen, J. Vergniol, C. Barthe, Juliette Foucher, Faïza Chermak, Brigitte Le Bail, Wassil Merrouche, P.‐H. Bernard · 2013 · Alimentary Pharmacology & Therapeutics
11. The Diagnostic Value of the FIB-4 Index for Staging Hepatitis B-Related Fibrosis: A Meta-Analysis
    Yuanyuan Li, Yu Chen, Ying Y. Zhao · 2014 · PLoS ONE
12. Aspartate aminotransferase to platelet ratio and fibrosis‐4 as biomarkers in biopsy‐validated pediatric cystic fibrosis liver disease
    Daniel H. Leung, Mahjabeen Khan, Charles Gene Minard, Danielle Guffey, Louise E. Ramm, Andrew Donald Clouston, Gregory C. Miller, Peter J. Lewindon, Ross W. Shepherd, Grant A. Ramm · 2015 · Hepatology
13. A novel spleen‐dedicated stiffness measurement by FibroScan® improves the screening of high‐risk oesophageal varices
    Horia Ştefănescu, Giovanni Marasco, Paul Calès, Mirella Fraquelli, Matteo Rosselli, Nathalie Ganne‐Carrié, Victor de Lédinghen, Federico Ravaioli, Antonio Colecchia, Corina A. Rusu et al. · 2019 · Liver International
14. Noninvasive tests for liver disease, fibrosis, and cirrhosis: Is liver biopsy obsolete?
    Emily Carey, William D. Carey · 2010 · Cleveland Clinic Journal of Medicine
15. Physiologic Frailty and Fragility Fracture in HIV-Infected Male Veterans
    Julie A. Womack, Joseph Lucien Goulet, Cynthia L. Gibert, Cynthia Brandt, Melissa Skanderson, Barbara Gulanski, David Rimland, Maria C. Rodriguez‐Barradas, Janet Tate, Michael T. Yin et al. · 2013 · Clinical Infectious Diseases
16. Short‐term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct‐acting anti‐viral treatment
    Eiichi Ogawa, Norihiro Furusyo, Hideyuki Nomura, Kazufumi Dohmen, N. Higashi, Kazuhiro Takahashi, A. Kawano, Koichi Azuma, Takeaki Satoh, Makoto Nakamuta et al. · 2017 · Alimentary Pharmacology & Therapeutics
17. Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD
    Beom Kyung Kim, Nobuharu Tamaki, Kento Imajo, Masato Yoneda, Nancy Sutter, Jinho Jung, Lin Tuo, Xin Ming Tu, Jaclyn Bergstrom, Khang Nguyen et al. · 2022 · Journal of Hepatology
18. Nonalcoholic fatty liver disease – current status and future directions
    Demir, Münevver, Lang, Sonja, Steffen, Hans‐Michael · 2015 · Journal of Digestive Diseases
19. Improvement of liver stiffness in patients with hepatitis C virus infection who received direct‐acting antiviral therapy and achieved sustained virological response
    Toshifumi Tada, Takashi Kumada, Hidenori Toyoda, Kazuyuki Mizuno, Yasuhiro Sone, Saki Kataoka, Shinichi Hashinokuchi · 2017 · Journal of Gastroenterology and Hepatology
20. Diagnostic Accuracy of APRI, AAR, FIB-4, FI, King, Lok, Forns, and FibroIndex Scores in Predicting the Presence of Esophageal Varices in Liver Cirrhosis
    Han Deng, Xingshun Qi, Xiaozhong Guo · 2015 · Medicine
21. Do Biomarkers of Inflammation, Monocyte Activation, and Altered Coagulation Explain Excess Mortality Between HIV Infected and Uninfected People?
    Kaku So‐Armah, Janet P. Tate, Chung‐Chou H. Chang, Adeel Ajwad Butt, Mariana Gerschenson, Cynthia L. Gibert, David A. Leaf, David Rimland, Maria C. Rodriguez‐Barradas, Matthew Jay Budoff et al. · 2016 · JAIDS Journal of Acquired Immune Deficiency Syndromes
22. Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C
    S. M. Martinez, Guillermo Fernández‐Varo, Patricia González, E. Sampson, Miquel Bruguera, Miquel Navasa, Wladimiro Jiménez, Jose María Sánchez-Tapias, Xavier Forns · 2010 · Alimentary Pharmacology & Therapeutics
23. The validity of serum markers for fibrosis staging in chronic hepatitis B and C
    J. Li, Stuart C. Gordon, Loralee B. Rupp, T. Zhang, Joseph A. Boscarino, Vinutha Vijayadeva, Mark A. Schmidt, Mei Lü, the Chronic Hepatitis Cohort Study (CHeCS) Investigators · 2014 · Journal of Viral Hepatitis
24. Prevalence of Liver Steatosis and Fibrosis Detected by Transient Elastography in Adolescents in the 2017–2018 National Health and Nutrition Examination Survey
    Stefano Ciardullo, Tommaso Monti, Gianluca Perseghin · 2020 · Clinical Gastroenterology and Hepatology
25. The accuracy of the FIB‐4 index for the diagnosis of mild fibrosis in chronic hepatitis B
    Vincent Olivier Mallet, Valérie Dhalluin-Venier, C. Roussin, Marc Bourlière, Mario Pettinelli, Claude Giry, Anaïs Vallet‐Pichard, Hélène Fontaine, Stanislas Pol · 2008 · Alimentary Pharmacology & Therapeutics
26. Biomarkers of liver fibrosis
    Leon Anton Adams · 2010 · Journal of Gastroenterology and Hepatology
27. Risk Factors for Hospitalization and Medical Intensive Care Unit (MICU) Admission Among HIV-Infected Veterans
    Kathleen M. Akgün, Kirsha S. Gordon, Margaret A. Pisani, Terri R. Fried, Kathleen A. McGinnis, Janet P. Tate, Adeel Ajwad Butt, Cynthia L. Gibert, Laurence Huang, Maria C. Rodriguez‐Barradas et al. · 2012 · JAIDS Journal of Acquired Immune Deficiency Syndromes
28. Clinical prediction of HBV and HCV related hepatic fibrosis using machine learning
    Runmin Wei, Jingye Wang, Xiaoning Wang, Guoxiang Xie, Yixing Wang, Hua Zhang, Cheng‐Yuan Peng, Cynthia Rajani, Sandi Alexander Kwee, Ping Liu et al. · 2018 · EBioMedicine
29. Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non‐alcoholic fatty liver disease
    Mitsuko Inoue, Akinori Hayashi, Tomomi Taguchi, Riina Arai, Sayaka Sasaki, Koji Takano, Yusuke Inoue, Masayoshi Shichiri · 2018 · Journal of Diabetes Investigation
30. A Phase I Dose Escalation Study Demonstrates Quercetin Safety and Explores Potential for Bioflavonoid Antivirals in Patients with Chronic Hepatitis C
    Nu T. Lu, Catherine M. Crespi, Natalie M Liu, James Q. Vu, Yasaman Ahmadieh, Sheng Wu, Sherry S.J. Lin, Amy C. McClune, Francisco Antonio Durazo, Sammy Saab et al. · 2015 · Phytotherapy Research
31. Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non‐alcoholic fatty liver disease
    Peter J. Eddowes, Natasha McDonald, Nigel P. Davies, Scott I K Semple, Timothy James Kendall, James A. Hodson, Philip Noel Newsome, Robert Flintham, Roman Wesołowski, L. Blake et al. · 2017 · Alimentary Pharmacology & Therapeutics
32. Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations
    Zobair M. Younossi, Mazen Noureddin, David Bernstein, Paul Yien Kwo, Mark W. Russo, Mitchell L. Shiffman, Ziad H Younes, Manal F. Abdelmalek · 2020 · The American Journal of Gastroenterology
33. Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity
    Marco A. Arrese, Juan Pablo Arab, Francisco Barrera M., Benedikt K. Kaufmann, Luca V. C. Valenti, Ariel E. Feldstein · 2021 · Seminars in Liver Disease
34. Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD
    Stefania Di Mauro, Alessandra Scamporrino, Agnese Filippello, Antonino Di Pino, Roberto Scicali, Roberta Malaguarnera, Francesco Purrello, Salvatore Piro · 2021 · International Journal of Molecular Sciences
35. Adult‐onset cystic fibrosis liver disease: Diagnosis and characterization of an underappreciated entity
    Christopher Koh, Sasan Sakiani, Pallavi Surana, Xiongce Zhao, Jason L. Eccleston, David Erwin Kleiner, David W. Herion, T. Jake Liang, Jay H. Hoofnagle, Milica S. Chernick et al. · 2017 · Hepatology
36. HIV Mono-infection Is Associated With FIB-4 - A Noninvasive Index of Liver Fibrosis - in Women
    Jason T. Blackard, Jeffrey A. Welge, Lynn E. Taylor, Kenneth Hugh Mayer, Robert S. Klein, David D. Celentano, Denise J. Jamieson, L. Gardner, Kenneth E. Sherman · 2011 · Clinical Infectious Diseases
37. The Evaluation of Hepatic Fibrosis Scores in Children with Nonalcoholic Fatty Liver Disease
    Sana Mansoor, Lisa M. Yerian, Rohit Kohli, Stavra A. Xanthakos, Paul Angulo, Simon C. Ling, Rocío López, Christine A. Carter-Kent, Ariel E. Feldstein, Naim Alkhouri · 2014 · Digestive Diseases and Sciences
38. A New Combination of Blood Test and Fibroscan for Accurate Non-Invasive Diagnosis of Liver Fibrosis Stages in Chronic Hepatitis C
    Jérôme Boursier, Victor de Lédinghen, Jean‐Pierre Zarski, Marie‐Christine Rousselet, Nathalie Stürm, Juliette Foucher, Vincent Leroy, Isabelle Fouchard‐Hubert, Sandrine Bertrais, Yves Gallois et al. · 2011 · The American Journal of Gastroenterology
39. Aberrant hepatic lipid metabolism associated with gut microbiota dysbiosis triggers hepatotoxicity of novel PFOS alternatives in adult zebrafish
    Qiyu Wang, Jing Huang, Shuai Liu, Caiyun Wang, Yuanxiang Jin, Hong Lai, Wenqing Tu · 2022 · Environment International
40. FIB-4: A simple, inexpensive and accurate marker of fibrosis in HCV-infected patients
    Anaïs Vallet‐Pichard, Vincent Olivier Mallet, Stanislas Pol · 2006 · Hepatology
41. Splenic Elasticity Measured with Real-time Tissue Elastography Is a Marker of Portal Hypertension
    Masashi Hirooka, Hironori Ochi, Yohei Koizumi, Yoshiyasu Kisaka, Masanori Abe, Yoshio Ikeda, Bunzo Matsuura, Yoichi Hiasa, Morikazu Onji · 2011 · Radiology
42. Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy?
    Jun Liong Chin, Michael Pavlides, Ahmad Moolla, John Denis Ryan · 2016 · Frontiers in Pharmacology
43. Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross‐sectional analysis of 2011‐2014 National Health and Nutrition Examination Survey
    Robert J. Wong, B. Liu, Taft P. Bhuket · 2017 · Alimentary Pharmacology & Therapeutics
44. Prospective Evaluation of FibroScan for the Diagnosis of Hepatic Fibrosis Compared with Liver Biopsy/AST Platelet Ratio Index and FIB-4 in Patients with Chronic HBV Infection
    Xia Zhu, Lichun Wang, En‐Qiang Chen, Xue-Bing Chen, Li-Yu Chen, Li Liu, Xue-Zhong Lei, Cong Liu, Hong Tang · 2011 · Digestive Diseases and Sciences
45. Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases
    Mohammed Eslam, Aijaz Ahmed, Jean‐Pierre Després, Vivekanand Jha, Jason C. G. Halford, Jack Tan Wei Chieh, David C.H. Harris, Masaomi Nangaku, Stephen Colagiuri, Giovanni Targher et al. · 2021 · The Lancet. Gastroenterology & hepatology
46. Diagnosis of liver fibrosis using FibroScan and other noninvasive methods in patients with hemochromatosis: A prospective study
    Xavier Adhoute, Juliette Foucher, David Laharie, Éric Terrebonne, J. Vergniol, Laurent Castéra, B. Lovato, Elise Chanteloup, Wassil Merrouche, Patrice Couzigou et al. · 2008 · Gastroentérologie Clinique et Biologique
47. Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?
    Stuart McPherson, Quentin Mark Anstee, Elsbeth Henderson, Christopher Paul Day, Alastair D. Burt · 2013 · European Journal of Gastroenterology & Hepatology
48. Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population
    Xiaolin Liu, Qin Pan, Rui-Nan Zhang, Feng Shen, Shiyan Yan, Chao Sun, Zhengjie Xu, Yuanwen Chen, Jian‐Gao Fan · 2016 · World Journal of Gastroenterology
49. A Frailty-Related Phenotype Before HAART Initiation as an Independent Risk Factor for AIDS or Death After HAART Among HIV-Infected Men
    Loïc Desquilbet, Lisa P. Jacobson, Linda P. Fried, John Phair, Beth D. Jamieson, M. Holloway, Joseph B. Margolick · 2011 · The Journals of Gerontology Series A
50. Effectiveness of sofosbuvir‐based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans
    Lisa I. Backus, Pamela S. Belperio, Troy A. Shahoumian, T. P. Loomis, Larry A. Mole · 2015 · Alimentary Pharmacology & Therapeutics
51. Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels
    Samer Gawrieh, Laura Wilson, Oscar W. Cummings, Jeanne M. Clark, Rohit Seth Loomba, Bilal Hameed, Manal F. Abdelmalek, Srinivasan Dasarathy, Brent A. Neuschwander‐Tetri, Kris V. Kowdley et al. · 2019 · The American Journal of Gastroenterology
52. E-AHPBA-ESSO-ESSR Innsbruck consensus guidelines for preoperative liver function assessment before hepatectomy
    Primavesi, Florian, Maglione, Manuel, Cipriani, Federica, Denecke, Timm, Oberkofler, Christian E, Starlinger, Patrick, Dasari, Bobby V M, Heil, Jan, Sgarbura, Olivia, Søreide, Kjetil et al. · 2023 · British Journal of Surgery
53. A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis
    Jérôme Boursier, Victor de Lédinghen, Vincent Leroy, Rodolphe Anty, Sven Francque, Dominique Salmon, Adrien Lannes, Sandrine Bertrais, Frédéric Oberti, Isabelle Fouchard‐Hubert et al. · 2017 · Journal of Hepatology
54. A comparison of four fibrosis indexes in chronic HCV: Development of new fibrosis-cirrhosis index (FCI)
    Waqar Ahmad, Bushra Ijaz, Fouzia T Javed, Sana Gull, Humera Kausar, Muhammad Tahir Sarwar, Sultan Asad, Imran Shahid, Aleena Sumrin, Saba Khaliq et al. · 2011 · BMC Gastroenterology
55. Serum Interleukin‐8, Osteopontin, and Monocyte Chemoattractant Protein 1 Are Associated With Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
    Oliver Glass, Ricardo Henao, Keyur Patel, Cynthia D. Guy, Hans J. Gruss, Wing‐Kin Syn, Cynthia A. Moylan, Robert D. Streilein, Russell P. Hall, Anna Mae Diehl et al. · 2018 · Hepatology Communications
56. Low muscle mass and low muscle strength associate with nonalcoholic fatty liver disease
    Da Gan, Lu Wang, Menghan Jia, Yuan Ru, Yiyun Ma, Weifang Zheng, Xueyin Zhao, Fei Yang, Tianru Wang, Yun Mu et al. · 2019 · Clinical Nutrition
57. Liver fibrosis on account of chronic hepatitis C is more severe in HIV‐positive than HIV‐negative patients despite antiretroviral therapy
    Victor de Lédinghen, Pablo Barreiro, Juliette Foucher, Pablo Labarga, Laurent Castéra, Eugenia Vispo, Pierre–Henri Bernard, Luz Martín‐Carbonero, Didier Neau, Pilar García‐Gascó et al. · 2008 · Journal of Viral Hepatitis
58. Systematic review with meta‐analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B
    Marion Houot, Yen Ngo, Mona Munteanu, Sébastien Marque, Thierry Poynard · 2015 · Alimentary Pharmacology & Therapeutics
59. Risk factors of hepatocellular carcinoma development in non‐cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection
    Hidenori Toyoda, Takashi Kumada, Toshifumi Tada, Seiki Kiriyama, Makoto Tanikawa, Yasuhiro Hisanaga, Akira Kanamori, Shusuke Kitabatake, Takanori Ito · 2015 · Journal of Gastroenterology and Hepatology
60. Simtuzumab treatment of advanced liver fibrosis in HIV and HCV ‐infected adults: results of a 6‐month open‐label safety trial
    Eric G. Meissner, Mary E. McLaughlin, Lindsay Matthews, Ahmed M. Gharib, Bradford J. Wood, Elliot B. Levy, Ralph Sinkus, Kimmo I. Virtaneva, Dan E. Sturdevant, Craig Martens et al. · 2016 · Liver International
61. HOMA‐IR : An independent predictor of advanced liver fibrosis in nondiabetic non‐alcoholic fatty liver disease
    Hideki Fujii, Kento Imajo, Masato Yoneda, Takashi Nakahara, Hideyuki Hyogo, Hirokazu Takahashi, Tasuku Hara, Saiyu Tanaka, Yoshio Sumida, Yuichiro Eguchi et al. · 2019 · Journal of Gastroenterology and Hepatology
62. Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease
    Zhang, Xinrong, Wong, Grace Lai‐Hung, Yip, Terry Cheuk‐Fung, Tse, Yee‐Kit, Liang, Lilian Yan, Hui, Vicki Wing‐Ki, Lin, Huapeng, Li, Guan‐Lin, Lai, Jimmy Che‐To, Chan, Henry Lik‐Yuen et al. · 2022 · Hepatology
63. Albumin, white blood cell count, and body mass index improve discrimination of mortality in HIV-positive individuals
    Janet P. Tate, Jonathan A C Sterne, Amy C. Justice · 2019 · AIDS
64. Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease
    Stefano Ballestri, Alessandro Mantovani, Enrica Baldelli, Simonetta Lugari, Mauro Maurantonio, Fabio Nascimbeni, Alessandra Marrazzo, Dante Romagnoli, Giovanni Targher, Amedeo Lonardo · 2021 · Diagnostics
65. Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management
    Amedeo Lonardo, Juan Pablo Arab, Marco A. Arrese · 2021 · Advances in Therapy
66. Circulating markers of liver fibrosis progression
    Peter Jarčuška, Martin Janíčko, Eduard Veselíny, Pavol Jarčuška, Ľubomír Skladaný · 2010 · Clinica Chimica Acta
67. Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre‐disposition pending between fiction and reality
    Olav Axel Gressner, Ralf Weiskirchen, Axel M. Gressner · 2007 · Journal of Cellular and Molecular Medicine
68. Liver Fibrosis Determination
    Michelle Lai, Nezam H. Afdhal · 2019 · Gastroenterology Clinics of North America
69. Diffusion-weighted MRI-based Virtual Elastography for the Assessment of Liver Fibrosis
    Kromrey, Marie-Luise, Le Bihan, Denis, Ichikawa, Shintaro, Motosugi, Utaroh · 2020 · Radiology
70. ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD
    Corey, Kathleen E., Pitts, Rebecca, Lai, Michelle, Loureiro, Joseph, Masia, Ricard, Osganian, Stephanie A., Gustafson, Jenna L., Hutter, Matthew M., Gee, Denise W., Meireles, Ozanan R. et al. · 2022 · Journal of Hepatology
71. Microbiota diversity in nonalcoholic fatty liver disease and in drug-induced liver injury
    Cristina Rodriguez, Bernard Taminiau, Alberto García-García, Alejandro Cueto‐Sánchez, Mercedes Robles‐Díaz, Aida Ortega‐Alonso, Flores Martín‐Reyes, Georges Daube, Judith Sanabria‐Cabrera, Miguel Jiménez Pérez et al. · 2022 · Pharmacological Research
72. Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: The fibrovic study – ANRS HC02
    P. Cacoub, Fabrice Carrat, Pierre Bédossa, Jérôme Lambert, Guillaume Pénaranda, Christian Perronne, Stanislas Pol, Philippe Halfon · 2008 · Journal of Hepatology
73. Haemostasis and thrombosis in liver disease
    Lara N. Roberts, Raj Patel, Roopen Arya · 2009 · British Journal of Haematology
74. Does the Functional Liver Imaging Score Derived from Gadoxetic Acid–enhanced MRI Predict Outcomes in Chronic Liver Disease?
    Nina Bastati, Lucian Beer, Mattias Mandorfer, Sarah Poetter‐Lang, Dietmar Tamandl, Yesim Bican, Michael Christoph Elmer, Henrik Einspieler, Georg Semmler, Benedikt Simbrunner et al. · 2019 · Radiology
75. Changes in liver stiffness measurements and fibrosis scores following sofosbuvir based treatment regimens without interferon
    Aisha Mahmoud Elsharkawy, Shereen Abdel Alem, Rabab Fouad, Maissa El Raziky, Wafaa Elakel, Mahmoud Abdo, Omnia Tantawi, Mohamed AbdAllah, Marc Bourlière, Gamal Esmat · 2017 · Journal of Gastroenterology and Hepatology
76. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease
    Katharina Staufer, Emina Halilbasic, Walter Spindelboeck, Magdalena Eilenberg, Gerhard Prager, Vanessa Stadlbauer, Andreas Posch, Petra Munda, Rodrig Marculescu, Barbara Maria Obermayer-Pietsch et al. · 2019 · United European Gastroenterology Journal
77. The Development of the Pediatric NAFLD Fibrosis Score (PNFS) to Predict the Presence of Advanced Fibrosis in Children with Nonalcoholic Fatty Liver Disease
    Naim Alkhouri, Sana Mansoor, Paola Giammaria, Daniela Liccardo, Rocío López, Valério Nobili · 2014 · PLoS ONE
78. Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfected patients with compensated liver cirrhosis
    Nicolás Merchante, Antonio Rivero‐Juárez, Francisco Téllez, Dolores Merino, Maria José Ríos-Villegas, Manuel Márquez, Mohamed Omar, Juan Macı́as, Ángela Camacho, Montserrat Pérez‐Pérez et al. · 2012 · Hepatology
79. Relationship Between Alcohol Use Categories and Noninvasive Markers of Advanced Hepatic Fibrosis in HIV-Infected, Chronic Hepatitis C Virus–Infected, and Uninfected Patients
    Joseph K. Lim, Janet P. Tate, Shawn L. Fultz, Joseph Lucien Goulet, Joseph C. Conigliaro, KENDALL J. BRYANT, Adam J. Gordon, Cynthia L. Gibert, David Rimland, Matthew Bidwell Goetz et al. · 2014 · Clinical Infectious Diseases
80. Machine Learning-based Development and Validation of a Scoring System for Screening High-Risk Esophageal Varices
    Tien Sy Dong, Amir Kalani, Elizabeth S. Aby, Long B. Le, Kayti Luu, Meg Hauer, Rahul Kamath, Keith D. Lindor, James H. Tabibian · 2019 · Clinical Gastroenterology and Hepatology
81. Significant decrease in Faecalibacterium among gut microbiota in nonalcoholic fatty liver disease: a large BMI- and sex-matched population study
    Chikara Iino, Tetsu Endo, Kenichiro Mikami, Takuma Hasegawa, Masayo Kimura, Naoya Sawada, Shigeyuki Nakaji, Shinsaku Fukuda · 2019 · Hepatology International
82. Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients
    Jihye Kim, Wonseok Kang, Dong Hyun Sinn, Geum‐Youn Gwak, Yong‐Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik · 2020 · Clinical and Molecular Hepatology
83. The role of fibrosis index FIB-4 in predicting liver fibrosis stage and clinical prognosis: A diagnostic or screening tool?
    Xiaolan Xu, Lushun Jiang, Chensi Wu, Liya Pan, Zhuoqi Lou, Chunting Peng, Yin Dong, Bing Ruan · 2021 · Journal of the Formosan Medical Association
84. Motivational interviewing with personalized feedback to reduce alcohol use in HIV-infected men who have sex with men: A randomized controlled trial.
    Kahler, Christopher W., Pantalone, David W., Mastroleo, Nadine R., Liu, Tao, Bove, Gerald, Ramratnam, Bharat, Monti, Peter M., Mayer, Kenneth H. · 2018 · Journal of Consulting and Clinical Psychology
85. Referral pathways for patients with NAFLD based on non‐invasive fibrosis tests: Diagnostic accuracy and cost analysis
    Catriona Crossan, Avik Majumdar, Ankur Srivastava, Douglas Thorburn, William M. Rosenberg, Massimo Pinzani, Louise Longworth, Emmanuel A. Tsochatzis · 2019 · Liver International
86. Impact of Implementing a “FIB‐4 First” Strategy on a Pathway for Patients With NAFLD Referred From Primary Care
    Tracy Davyduke, Puneeta Tandon, Mustafa Al‐Karaghouli, Juan G. Abraldeṣ, Mang M. Ma · 2019 · Hepatology Communications
87. Statin Use and the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B
    Myung Ji Goh, Dong Hyun Sinn, Seonwoo Kim, Sook‐Young Woo, Hyun Cho, Wonseok Kang, Geum‐Youn Gwak, Yong‐Han Paik, Moon Seok Choi, Joon Hyeok Lee et al. · 2019 · Hepatology
88. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial
    Andrew Radley, Marijn de Bruin, Sarah Karen Inglis, Peter T. Donnan, Adrian Hapca, Stephen T. Barclay, Andrew G. Fraser, John Francis Dillon · 2020 · The Lancet. Gastroenterology & hepatology
89. The Enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease
    Katharine M. Irvine, Leesa F. Wockner, Mihir Shanker, Kevin J. Fagan, Leigh Ula Horsfall, Linda Maria Fletcher, Jacobus P J Ungerer, Carel Jacobus Pretorius, Gregory C. Miller, Andrew Donald Clouston et al. · 2015 · Liver International
90. Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011–2016
    Michael Huan Le, Yee Hui Yeo, Ramsey C Cheung, Vincent Wai‐Sun Wong, Mindie H. Nguyen · 2020 · Journal of Internal Medicine
91. Review article: the prevention and reversal of hepatic fibrosis in autoimmune hepatitis
    Albert J. Czaja · 2014 · Alimentary Pharmacology & Therapeutics
92. Factors associated with phosphatidylethanol (PEth) sensitivity for detecting unhealthy alcohol use: An individual patient data meta‐analysis
    Hahn, Judith A., Murnane, Pamela M., Vittinghoff, Eric, Muyindike, Winnie R., Emenyonu, Nneka I., Fatch, Robin, Chamie, Gabriel, Haberer, Jessica E., Francis, Joel M., Kapiga, Saidi et al. · 2021 · Alcoholism: Clinical and Experimental Research
93. Non-invasive diagnosis of liver fibrosis in chronic hepatitis C
    Leonardo de Lucca Schiavon · 2014 · World Journal of Gastroenterology
94. Management of Patients Coinfected With HCV and HIV: A Close Look at the Role for Direct-Acting Antivirals
    Susanna Naggie, Mark Sulkowski · 2012 · Gastroenterology
95. Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants
    Daniele Pastori, Gregory Y.H. Lip, Alessio Farcomeni, Francesco Del Sole, Angela Sciacqua, Francesco Perticone, Rossella Marcucci, Elisa Grifoni, Pasquale Pignatelli, Francesco Violi et al. · 2018 · International Journal of Cardiology
96. Noninvasive Biomarkers of Liver Fibrosis: An Overview
    Hind I. Fallatah · 2014 · Advances in Hepatology
97. Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease
    Cyrielle Caussy, Veeral H. Ajmera, Puneet Puri, Cynthia L. Hsu, Shirin Bassirian, Mania Mgdsyan, Seema Singh, Claire Faulkner, Mark A. Valasek, Emily Rizo et al. · 2018 · Gut
98. Metabolic Dysfunction–Associated Fibrosis 5 (MAF-5) Score Predicts Liver Fibrosis Risk and Outcome in the General Population With Metabolic Dysfunction
    Laurens A. van Kleef, Sven Francque, Jhon Edison Prieto Ortíz, Milan J. Sonneveld, Carlos B Sanchez-Luque, Robin G Prieto-Ortiz, Wilhelmus Josephus Kwanten, Luisa Vonghia, An Verrijken, Christophe E.M. De Block et al. · 2024 · Gastroenterology
99. Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study
    de Vries, Elisabeth M.G., Färkkilä, Martti, Milkiewicz, Piotr, Hov, Johannes R., Eksteen, Bertus, Thorburn, Douglas, Chazouillères, Olivier, Pares, Albert, Nygård, Ståle, Gilja, Odd H. et al. · 2017 · Liver International
100. Liver Fibrosis Progression in Hepatitis C Virus Infection After Seroconversion
     Adeel Ajwad Butt, Peng Yan, Vincent Lo Re, David Rimland, Matthew Bidwell Goetz, David A. Leaf, Matthew S. Freiberg, Marina B. Klein, Amy C. Justice, Kenneth E. Sherman · 2014 · JAMA Internal Medicine